1,083
Participants
Start Date
June 30, 2004
Primary Completion Date
January 31, 2005
Study Completion Date
January 31, 2005
No intervention
No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
Tucson
Laguna Woods
Northridge
Oceanside
Paramount
San Diego
San Francisco
Hamden
Hartford
New Haven
Fort Lauderdale
Miami
North Miami
Oscala F
St. Petersburg
West Palm Beach
Atlanta
Chicago
Paducah
Glen Burnie
Rockville
Boston
Pittsfield
Farmington Hills
Kalamazoo
Clementon
Ridgewood
Summit
Albany
New Hyde Park
New York
Rochester
Staten Island
The Bronx
Durham
Columbus
Toledo
Tulsa
Portland
Pittsburgh
East Providence
Providence
Austin
Dallas
Houston
Wichita Falls
Bennington
Richmond
Tacoma
Middleton
Buenos Aires
Córdoba
Adelaide
Christchurch Nz
Hornsby Streets
Kew
Parkville
Perth
Randwick
Woodville
Graz
Innsbruck
Vienna
Aalst
Antwerp
Hasselt
Jumet
Leuven
Liège
Merksem
Reet
Roeselare
Wilrijk
Edmonton
Vancouver
Moncton
Saint John
Halifax
Barrie
Hamilton
Kingston
London
North York
Ottawa
Toronto
Greenfield Park
Pointe-Claire
Québec
Verdun
Saskatoon
London
Montreal
North York
T2n
Chomutov
Dobřany
Hluboká nad Vltavou
Kolín
Opava
Praha 8 N/A
Rennes Cedex
Ústí nad Labem
Helsinki
Kuopio
Toulouse
Berlin
Frankfurt am Main
Mannheim
München
Nuremberg
Ulm
Haifa
Petach Tikya
Ramat Gan
Tel Aviv
's-Hertogenbosch
Alkmaar
Amsterdam
Breda
Maastricht
Gdansk
Katowice Poland
Lodz
Mosina Poland
Poznan
Poznan Poland
Warsaw
Barakaldo Vizcaya S/N
Barcelona
Madrid
Terrasa Barcelona N/A
Linköping
Lund
Malmo
Mölndal
Piteå
Stockholm
Umeå
Bradford
Bristol
Clydebank
New Milton
Southampton
Swindon
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY